<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD02880000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q15661</UniProt_ID>
  <Seq_Length>275</Seq_Length>
  <Molecule_Weight>30515</Molecule_Weight>
  <KEGG_ID>hsa:7177</KEGG_ID>
  <Orthology_ID>K01340</Orthology_ID>
  <EBI_ID>EBI-1761369</EBI_ID>
  <Function_Summary>Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type (By similarity).</Function_Summary>
  <Catalytic_Mechanism>Preferential cleavage: Arg-|-Xaa, Lys-|-Xaa, but with more restricted specificity than trypsin.</Catalytic_Mechanism>
  <Pfam_ID>PF00089:Trypsin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>2</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Tryptase beta 1</Alias>
      <Alias>Tryptase-III</Alias>
      <Alias>Tryptase alpha II</Alias>
      <Alias>Tryptase I</Alias>
      <Alias>Tryptase-1</Alias>
      <Alias>Mast cell alpha II tryptase</Alias>
      <Alias>Tryptase alpha-1</Alias>
      <Alias>Tryptase-I</Alias>
      <Alias>Mast cell beta I tryptase</Alias>
      <Alias>Tryptase beta I</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).</Detail>
      <Keyword>Protein binding</Keyword>
      <Ontology_ID>GO:0005515</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>OBSOLETE. Catalysis of the preferential cleavage of Arg-Xaa, Lys-Xaa, but with more restricted specificity than trypsin.</Detail>
      <Keyword>Tryptase activity</Keyword>
      <Ontology_ID>GO:0030019</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>205</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>23</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>18</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>132</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>216</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>136</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>52</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>170</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>141</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>215</Position>
      <Original>Thr</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>221</Position>
      <Original>Gln</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>3</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>15</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>245</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>141</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>53</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>263</Position>
      <Original>Tyr</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>28</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>29</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>116</Position>
      <Original>Ala</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>85</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>118</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>76</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>133</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>115</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>51</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>162</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>168</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Reactions, triggered in response to the presence of a foreign body or the occurrence of an injury, which result in restriction of damage to the organism attacked or prevention/recovery from the infection caused by the attack.</Detail>
      <Keyword>Defense response</Keyword>
      <Ontology_ID>GO:0006952</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MLNLLLLALPVLASRAYAAPAPGQALQRVGIVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGADIALLELEEPVNVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP</Protein_Seq>
    <DNA_Seq>ACCAGCTGACAGGTGGAGCTGCCAGTCTCCAGTGCTCAGCCCTCAGCGGGGCCTGCCTGGCAGCCCCACACACAGAGGGCATCGGGGTGGCGGGGGCACGTGTTACACGGGGGCCCTGGGTCTGAGTCATCCACTTCCTCCGAGTCTGGATGGGAGGACCCAGCGCCCCTCCTCCGCCCCCTCCTGATCTGGAAGGATAAATGGGGAGGGGAGAGCCACTGGGTAGAAGGAACAGGGAGTGGCCAGGGTAAGTCCCCACTCTCAGAGACCCTGACATCAGCGTCACCTGGAGCAGAGTGGCCCAGCCTCAGACTCAGAGCACCAAGACCCAGGCCCGCAGGCCTGGACCCACCCCGGTCCCCCCGTCCCAGCTCCATTCTTCACCCCACAATCTGTAGCCCCCAGCCCTGCCCTGTGAGGCCCGGCCAGGCCCACGATGCTCCTCCTTGCTCCCCAGATGCTGAATCTGCTGCTGCTGGCGCTGCCCGTCCTGGCGAGCCGCGCCTACGCGGCCCCTGGTGAGTCCCAGCCGGGGTCCACCCTGCCCCTCACCACATTCCACAGGTCAGGGCCTGGGTGGGTTCTGGGGAGGTCGGGCTGGCCCCCCACACAGGGAAGGGCTGGGCCCAGGCCTGGGGCTGCTTCCTGGTCCTGACCTGGCACCTGCCCCAGCCCCAGGCCAGGCCCTGCAGCGAGTGGGCATCGTCGGGGGTCAGGAGGCCCCCAGGAGCAAGTGGCCCTGGCAGGTGAGCCTGAGAGTCCACGGCCCATACTGGATGCACTTCTGCGGGGGCTCCCTCATCCACCCCCAGTGGGTGCTGACCGCAGCGCACTGCGTGGGACCGTGAGTCTCCCGGGGCCTGGAGGGGTGGGGAAGGGCTGGATGTGAGCCCTGGCTCCCGGGTGCTCCTGGGGGCTGCCCAGGGCCCTGAGTGGGATCCTCCGCTGCCCAGGGACGTCAAGGATCTGGCCGCCCTCAGGGTGCAACTGCGGGAGCAGCACCTCTACTACCAGGACCAGCTGCTGCCGGTCAGCAGGATCATCGTGCACCCACAGTTCTACACCGCCCAGATCGGAGCGGACATCGCCCTGCTGGAGCTGGAGGAGCCGGTGAACGTCTCCAGCCACGTCCACACGGTCACCCTGCCCCCTGCCTCAGAGACCTTCCCCCCGGGGATGCCGTGCTGGGTCACTGGCTGGGGCGATGTGGACAATGATGGTGGGTCTGGGGACAGTGGAGGTGGGGCCAGGGTCTTAGCCACAGCCCAGCCCCTGGGTCCCTCTGGGCTCCAGGTGGGGGTTGCCCGGCCCCCTCCTGAGGCTGCACCCTCTTCCCCACCTGCAGAGCGCCTCCCACCGCCATTTCCTCTGAAGCAGGTGAAGGTCCCCATAATGGAAAACCACATTTGTGACGCAAAATACCACCTTGGCGCCTACACGGGAGACGACGTCCGCATCGTCCGTGACGACATGCTGTGTGCCGGGAACACCCGGAGGGACTCATGCCAGGTGGGCCCCGCCTGTCCCCCGCCCCCCGCCCCCCAACCCCCACTCCCAGGCCTGTTCGGCGAGCGCTGACCTCTGACCTTCCCAGGGCGACTCCGGAGGGCCCCTGGTGTGCAAGGTGAATGGCACCTGGCTGCAGGCGGGCGTGGTCAGCTGGGGCGAGGGCTGTGCCCAGCCCAACCGGCCTGGCATCTACACCCGTGTCACCTACTACTTGGACTGGATCCACCACTATGTCCCCAAAAAGCCGTGAGTCAGGCCTGGGTTGGCCACCTGGGTCACTGGAGGACCAACCCCTGCTGTCCAAAACACCACTGCTTCCTACCCAGGTGGCGACTGCCCCCCACACCTTCCCTGCCCCGTCCTGAGTGCCCCTTCCTGTCCTAAGCCCCCTGCTCTCTTCTGAGCCCCTTCCCCTGTCCTGAGGACCCTTCCCTATCCTGAGCCCCCTTCCCTGTCCTAAGCCTGACGCCTGCACCGGGCCCTCCAGCCCTCCCCTGCCCAGATAGCTGGTGGTGGGCGCTAATCCTCCTGAGTGCTGGACCTCATTAAAGTGCATGGAAATCACTGGTGTGCATCGCTGTGTTTCTGGTTGTGGATGTCACTGGGAGAGAAGGGGTCCAGGTGTGCTGAGGACACCTGCCACAGTGTGAGGTCCTAGCCCTCAAGGCACAGCCAGTCACCGTGGGAC</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Mast cells</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>TPSAB1</Gene_Name>
    <Gene_Alias>TPS1; TPS2; TPSB1</Gene_Alias>
    <Gene_ID>7177</Gene_ID>
    <Genbank_ACCN>NM_003294</Genbank_ACCN>
    <Protein_ACCN>NP_003285</Protein_ACCN>
    <HGNC_ID>12019</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/7177</Gene_URL>
    <UCSC_ID>uc010uux.2</UCSC_ID>
    <EMBL_ID>ENSG00000172236</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P27986</Uniprot_ID>
      <Gene_Name>PIK3R1</Gene_Name>
      <EBI_ID>EBI-79464</EBI_ID>
      <PPI_EBI_URL>EBI-1761369,EBI-79464</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P16333</Uniprot_ID>
      <Gene_Name>NCK1</Gene_Name>
      <EBI_ID>EBI-389883</EBI_ID>
      <PPI_EBI_URL>EBI-1761369,EBI-389883</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Cutaneous Mastocytosis</Disease_Name>
      <Disease_Detail>Cutaneous Mastocytosis</Disease_Detail>
      <Disease_DB>CTN014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cutaneous_mastocytosis?search=TPSAB1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Asthma</Disease_Name>
      <Disease_Detail>Asthma</Disease_Detail>
      <Disease_DB>AST005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/asthma?search=TPSAB1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Candida Glabrata</Disease_Name>
      <Disease_Detail>Candida Glabrata</Disease_Detail>
      <Disease_DB>CND006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/candida_glabrata?search=TPSAB1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dengue Shock Syndrome</Disease_Name>
      <Disease_Detail>Dengue Shock Syndrome</Disease_Detail>
      <Disease_DB>DNG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dengue_shock_syndrome?search=TPSAB1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Abdominal Aortic Aneurysm</Disease_Name>
      <Disease_Detail>Abdominal Aortic Aneurysm</Disease_Detail>
      <Disease_DB>ABD003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/abdominal_aortic_aneurysm?search=TPSAB1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase</PDB_Title>
      <PDB_ID>2ZEB</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZEB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-(1'-{[3-(methylsulfanyl)-2-benzothiophen- 1-yl]carbonyl}spiro[1-benzofuran
-3,4'-piperidin]- 5-yl)methanamine</Ligand_Name>
      <PubMed_Title>Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives</PubMed_Title>
      <Author>Costanzo MJ, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Mar 15;18(6):2114-21. Epub  2008 Jan 30.</Journal>
      <PubMed_ID>18272363</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase</PDB_Title>
      <PDB_ID>2ZEC</PDB_ID>
      <Resolution>2.06</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZEC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>1-[1'-(3-phenylacryloyl)spiro[1-benzofuran- 3,4'-piperidin]-5-yl]methanamine</Ligand_Name>
      <PubMed_Title>Potent, nonpeptide inhibitors of human mast cell tryptase. Synthesis and biological evaluation of novel spirocyclic piperidine amide derivatives</PubMed_Title>
      <Author>Costanzo MJ, et al.</Author>
      <Journal>Bioorg Med Chem Lett.2008 Mar 15;18(6):2114-21. Epub  2008 Jan 30.</Journal>
      <PubMed_ID>18272363</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.cg.html</SCOP_URL>
    <CATH_Class>Mainly beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/2zeb</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Reference>Harvima IT, et al. Biochim.Biophys.Acta. 1988,956(2):133-139;Selwood T, et al. Arch Biochem Biophys. 2012, 519(2):131-143.</Site_Reference>
      <Site_Type>Morpheein model</Site_Type>
      <PubMed_ID>3048411;22182754</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.59</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/59.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00290003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02880002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>